Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322
- 1 May 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (5), 2333-2342
- https://doi.org/10.1128/aac.02566-12
Abstract
GSK1322322 is a novel peptide deformylase (PDF) inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections and hospitalized patients with community-acquired pneumonia. The activity of GSK1322322 was tested against a global collection of clinical isolates of Haemophilus influenzae (n = 2,370), Moraxella catarrhalis (n = 115), Streptococcus pneumoniae (n = 947), Streptococcus pyogenes (n = 617), and Staphylococcus aureus (n = 940), including strains resistant to one or more marketed antibiotics. GSK1322322 had an MIC90 of 1 μg/ml against M. catarrhalis and 4 μg/ml against H. influenzae, with 88.8% of β-lactamase-positive strains showing growth inhibition at that concentration. All S. pneumoniae strains were inhibited by ≤4 μg/ml of GSK1322322, with an MIC90 of 2 μg/ml. Pre-existing resistance mechanisms did not affect its potency, as evidenced by the MIC90 of 1 μg/ml for penicillin, levofloxacin, and macrolide-resistant S. pneumoniae. GSK1322322 was very potent against S. pyogenes strains, with an MIC90 of 0.5 μg/ml, irrespective of their macrolide resistance phenotype. This PDF inhibitor was also active against S. aureus strains regardless of their susceptibility to methicillin, macrolides, or levofloxacin, with an MIC90 of 4 μg/ml in all cases. Time-kill studies showed that GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥3-log10 decrease in the number of CFU/ml at 4× MIC within 24 h in 29 of the 33 strains tested. Given the antibacterial potency demonstrated against this panel of organisms, GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens.This publication has 28 references indexed in Scilit:
- Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic StewardshipClinical Infectious Diseases, 2009
- Antimicrobial Resistance inHaemophilus influenzaeClinical Microbiology Reviews, 2007
- Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus SpeciesAntimicrobial Agents and Chemotherapy, 2006
- Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical ImportanceAntimicrobial Agents and Chemotherapy, 2005
- Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other AgentsAntimicrobial Agents and Chemotherapy, 2004
- Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial speciesProtein Science, 2003
- Distinctive features of the two classes of eukaryotic peptide deformylasesJournal of Molecular Biology, 2001
- Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removalJournal of Molecular Biology, 1999
- Cleavage of the N-terminal formymlethionine residue from a bacteriophage coat protein in vitroJournal of Molecular Biology, 1973
- On the release of the formyl group from nascent proteinJournal of Molecular Biology, 1968